Alexander Gintsburg, head of the Gamaleya National Research Center of Epidemiology and Microbiology, said the personalized vaccine is designed to target malignant tumors using the patient's own genetic information. Developed with the help of artificial intelligence and mRNA technology, the injection is tailored to each patient to increase treatment effectiveness.

Scientists have completed the collection and analysis of patients' genetic data. Treatment will begin as soon as possible. The recruited patients will be equally divided between the Herzen Moscow Oncology Research Institute and the Blokhin National Medical Research Center of Oncology.

Illustration of the cancer vaccine research process. Photo: Vecteezy

Illustration of the cancer vaccine research process. Photo: Vecteezy

Veronika Skvortsova, head of the Federal Medical-Biological Agency, previously stated that the cancer vaccine demonstrated high efficacy in preclinical trials and is ready for clinical application. The vaccine's documentation has been submitted to the Ministry of Health for approval.

Unlike Covid-19 vaccines, which target a single viral antigen, the personalized cancer vaccine encodes multiple neoantigens specific to each patient, allowing the immune system to accurately identify and attack cancer cells. If successful, the project will be a turning point in Russia's public health strategy and could expand international collaboration, as several foreign medical institutions have expressed interest.

Van Ha (Tass, RT)